Manhattan Scientifics and Los Alamos National Laboratory Sign Licensing Partnership Agreement
January 20, 2009
Manhattan Scientifics (Pink Sheets:MHTX) today announced that it successfully completed and entered into an exclusive license agreement with the Los Alamos National Laboratory. This new agreement pertains to the improved manufacturing techniques and medical use applications for Los Alamos National Laboratory’s nano-structured metals and alloys technology.
Manhattan Scientifics recently announced FDA approval of its nano-titanium dental implants. Manhattan Scientifics’ Metallicum division is planning to manufacture these nano-titanium implants at Danlin Products, Manhattan Scientific’s affiliated manufacturing partner in Albuquerque, NM.
MHTX's nano-structured metals also have wide implications for use in the medical device and prosthetics industries including cardiovascular stents, dental implants, and replacements for hips, shoulders and knees. Clinical studies have shown that bone integrates with these new metals up to 20 times faster than with conventional metals. This means faster healing after surgery and ultimately longer life for nano-structured metal implants.
Manhattan Scientifics' acquisition of Metallicum Inc. was an important step towards formulating its new business model, positioning itself as a "green" technology development company.
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Manhattan Scientifics, Inc.
Marvin Maslow, Director of PR & IR, 917-923-3300
Herbert Strauss, +43-316-296-316
U.S. & Canadian Investor Relations
Hawk Associates: Frank Hawkins, 305-451-1888